Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Zhejiang Yangli Pharmaceutical Technology Co. Ltd. has 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 2 actions are split between 2 distinct examiners and 2 distinct art units. SAVITHA M RAO is the busiest examiner with 1 pending action. The distribution across 2 art units suggests that the company is pursuing different pharmaceutical sub-specialties.
Because each of the 2 pending office actions is assigned to a different examiner, there is no personnel overlap in the current workload. Practitioners must manage two separate prosecution tracks, each tailored to the specific examiner and art unit involved. This requires a versatile approach to handle the unique requirements of the 2 active matters.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §102 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| KWON, YONG SOK | 1 | 24.6% | +42.7% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | KWON, YONG SOK | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19296888 | PYRANOPYRIDINE COMPOUND, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF | RAO, SAVITHA M | 72d |
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | KWON, YONG SOK | — |
| Art Unit | Apps |
|---|---|
| 1691 | 1 |
| 1613 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19296888 | PYRANOPYRIDINE COMPOUND, PROCESS FOR PREPARING THE SAME, PHARMACEUTICAL COMPOSITION AND USE THEREOF | RAO, SAVITHA M | 1691 | §102 | Non-Final OA | 72d | Pending | Aug 11, 2025 |
| 18843719 | CRYSTAL FORM OF ISOCHROMAN COMPOUND | KWON, YONG SOK | 1613 | §112DP | Non-Final OA | — | Pending | Sep 04, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialZhejiang Yangli Pharmaceutical Technology Co. Ltd. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Savitha M Rao has the most, with 1 of Zhejiang Yangli Pharmaceutical Technology Co. Ltd.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
